Aurobindo Pharma buys 4 biosimilars from Swiss firm TL Biopharmaceutical

Aurobindo Pharma Limited has acquired four cell culture derived biosimilar products from Swiss firm TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo will develop, commercialise & market these products globally. The branded market size of these four biosimilars, three of them monoclonal antibodies, in oncology is very promising, claimed Aurobindo Pharma. Regulatory filing for these products is expected during the period of 2020-22.

Aurobindo is preparing to take its lead molecule from this transaction, a bevacizumab biosimilar, for clinical trials in 2017. Bevacizumab is an anti-antiogenesis drug used in